Treatment with anacetrapib increases HDL apoA-I and CETP levels

Reyes-Soffer G, Millar JS, Ngai C, et al.
Arterioscler Thromb Vasc Biol. 2016;36:published online ahead of print

Background

It has been shown that LDL-C-lowering therapy with statins decreases the risk of CVD events, but it is unclear whether the same result can be achieved by increasing HDL-C with CETP inhibition [1,2]. Relevant studies have come to the following conclusions:

• ILLUMINATE study: torcetrapib increased HDL-C by 60% - 100% but actually increased CVD events [3]
• dal-OUTCOMES study: dalcetrapib increased HDL-C by approximately 30% and had no effect on CVD events [4]
• ACCELERATE study: evacetrapib was stopped early because of insufficient efficacy on outcome endpoints [5]

The existing data raise questions regarding the pharmacological effects of CETP inhibition on reverse cholesterol transport [6]. Moreover, there is evidence with limited power, suggesting that the addition of atorvastatin to the CETP inhibitor torcetrapib, negates the torcetrapib benefits on the fractional clearance rate of apoA-I from plasma [7].
In the meantime, anacetrapib (ANA), another CETP inhibitor under development that increases HDL-C by up to 140% [8], is currently tested in the CVD outcomes study REVEAL [9].
The present randomised, placebo-controlled, double-blind study investigated the effects of ANA on the metabolism of HDL apoA-I and apoA-II and plasma CETP, with or without atorvastatin (ATV) therapy, in 39 individuals.

Main results

In the ATV-ANA group, 8 weeks of ANA treatment on a statin background resulted in:

• an increase in HDL-C (68.1%; P<0.001)
• a decrease in LDL-C (38.0%; P<0.001)
• no changes in TG
• increased plasma apoA-I concentrations (29.3%; P<0.001)
• increased apoA-II levels (11.9%; P<0.001)

In the PBO-ANA group:

• HDL-C increased (53.5%; P=0.055)
• LDL-C decreased (34.5%; P=0.039)
• TG levels decreased (24.5%; P=0.012)
• plasma apoA-I concentrations increased (29.7%; P<0.001)
• apoA-II levels increased (13.3%; P=0.008)

The increase in apoA-I pool size during ANA treatment was driven by a significant decrease in the HDL apoA-I fractional clearance rates (15.7% in the ATV-ANA and 20.7% in the PBO-ANA group; P=0.009 and P=0.029, respectively), without changes in the production rate. Importantly, the reductions in the fractional turnover of apoA-I were associated with an increase in both pre-β and larger α HDL subfractions. No significant changes in either apoA-II fractional clearance rate or production rate could be observed.  
• The cholesterol content in isolated HDL after ultracentrifugation increased:

• by 85.2% in the ATV-ANA group (P<0.001)
• by 97.8% in the PBO-ANA group (P<0.001)

Cholesteryl ester, which accounted for >80% of the total cholesterol content in the HDL fractions, increased:

• by 81.0% in the ATV-ANA group (P<0.001)
• by 89.8% in the PBO-ANA group (P<0.001)

The HDL-TG content decreased:

• by 53.7% in the ATV-ANA group (P<0.001)
• by 46.6% in the PBO-ANA group (P<0.001)

CETP mass increased because of a significant reduction in the fractional clearance rate of CETP with no change in the CETP production rate:

• by 108% in the ATV-ANA group (P<0.001)
• by 91.2% in the PBO-ANA group (P=0.002)

Conclusion

In this study, treatment with anacetrapib increased the HDL apoA-I and CETP levels by decreasing their fractional clearance rate. This is the first report of the effects of a CETP inhibitor on the metabolism of CETP.

Find this article online

References

1. Baigent C, Blackwell L, Emberson J, et al, Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 2010;376:1670–1681
2. Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18:1344–1346
3. Barter PJ, Caulfield M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109–2122
4. Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089–2099
5. Nicholls SJ, Lincoff AM, Barter PJ, et al. Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial. Am Heart J. 2015;170:1061–1069
6. Rader DJ, deGoma EM. Future of cholesteryl ester transfer protein inhibitors. Annu Rev Med. 2014;65:385–403
7. Brousseau ME, Diffenderfer MR, Millar JS, et al. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler Thromb Vasc Biol.2005;25:1057–1064
8. Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J.2009;157:352–360.e2
9. Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406–2415